TOR Mutations Confer Rapamycin Resistance by Preventing Interaction with FKBP12-Rapamycin (*)

The antifungal, immunosuppressive compound rapamycin arrests the cell cycle in G in both yeast cells and T-lymphocytes. Previous genetic studies in yeast identified mutations in three genes, FPR1 (FKBP12), TOR1, and TOR2, which confer rapamycin resistance, and genetic findings implicated the TOR proteins as direct targets of FKBP12-rapamycin. Consistent with this model, we find that modulating TOR1 and TOR2 expression alters rapamycin sensitivity. We describe several TOR2 mutations that confer rapamycin resistance. These mutations prevent FKBP12-rapamycin binding to TOR2, as assayed with the two-hybrid system. We find that TOR1 and the mammalian TOR homologue (mTOR) also bind FKBP12-rapamycin, and mutations corresponding to those in TOR2 similarly block FKBP12-rapamycin binding. We demonstrate that FKBP12 prolyl isomerase activity is not required for FKBP12-rapamycin binding to TOR and that a composite protein-drug surface contacts the TOR proteins. These studies confirm that the TOR proteins are direct targets of FKBP12-rapamycin, reveal that drug-resistant mutations prevent this association, and define structural features of these complexes.

[1]  R. S. Muir,et al.  Targets of immunophilin‐immunosuppressant complexes are distinct highly conserved regions of calcineurin A. , 1995, The EMBO journal.

[2]  S. Schreiber,et al.  Identification of an 11-kDa FKBP12-rapamycin-binding domain within the 289-kDa FKBP12-rapamycin-associated protein and characterization of a critical serine residue. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[3]  R. Abraham,et al.  Isolation of a Protein Target of the FKBP12-Rapamycin Complex in Mammalian Cells (*) , 1995, The Journal of Biological Chemistry.

[4]  M. Mclaughlin,et al.  Interaction between FKBP12-rapamycin and TOR involves a conserved serine residue. , 1994, The Journal of biological chemistry.

[5]  V. Berlin,et al.  RAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12/rapamycin complex. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[6]  James M. Roberts,et al.  lnterleukin-2-mediated elimination of the p27Kipl cyclin-dependent kinase inhibitor prevented by rapamycin , 1994, Nature.

[7]  R. S. Muir,et al.  Immunophilins interact with calcineurin in the absence of exogenous immunosuppressive ligands. , 1994, The EMBO journal.

[8]  H. Ogawa,et al.  An essential gene, ESR1, is required for mitotic cell growth, DNA repair and meiotic recombination in Saccharomyces cerevisiae. , 1994, Nucleic acids research.

[9]  J. Heitman,et al.  Yeast as model T cells , 1994 .

[10]  Paul Tempst,et al.  RAFT1: A mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs , 1994, Cell.

[11]  Stuart L. Schreiber,et al.  A mammalian protein targeted by G1-arresting rapamycin–receptor complex , 1994, Nature.

[12]  M. Mclaughlin,et al.  Yeast TOR (DRR) proteins: amino-acid sequence alignment and identification of structural motifs. , 1994, Gene.

[13]  W M Barnes,et al.  PCR amplification of up to 35-kb DNA with high fidelity and high yield from lambda bacteriophage templates. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[14]  L. Hartwell,et al.  Mitotic checkpoint genes in budding yeast and the dependence of mitosis on DNA replication and repair. , 1994, Genes & development.

[15]  J. Kunz,et al.  TOR1 and TOR2 are structurally and functionally similar but not identical phosphatidylinositol kinase homologues in yeast. , 1994, Molecular biology of the cell.

[16]  A. Marks,et al.  Rapamycin-FKBP12 blocks proliferation, induces differentiation, and inhibits cdc2 kinase activity in a myogenic cell line. , 1993, The Journal of biological chemistry.

[17]  S. Elledge,et al.  The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases , 1993, Cell.

[18]  William Arbuthnot Sir Lane,et al.  Isolation of the cyclosporin-sensitive T cell transcription factor NFATp. , 1993, Science.

[19]  R. Abraham,et al.  Rapamycin inhibition of interleukin-2-dependent p33cdk2 and p34cdc2 kinase activation in T lymphocytes. , 1993, The Journal of biological chemistry.

[20]  S. Schreiber,et al.  FKBP-rapamycin inhibits a cyclin-dependent kinase activity and a cyclin D1-Cdk association in early G1 of an osteosarcoma cell line. , 1993, The Journal of biological chemistry.

[21]  M. Mclaughlin,et al.  Dominant missense mutations in a novel yeast protein related to mammalian phosphatidylinositol 3-kinase and VPS34 abrogate rapamycin cytotoxicity , 1993, Molecular and cellular biology.

[22]  T. Curran,et al.  The T-cell transcription factor NFATp is a substrate for calcineurin and interacts with Fos and Jun , 1993, Nature.

[23]  J. Heitman,et al.  Identification of immunosuppressive drug targets in yeast , 1993 .

[24]  S. Fields.  The Two-Hybrid System to Detect Protein-Protein Interactions , 1993 .

[25]  P. Manivasakam,et al.  Introducing DNA into Yeast by Transformation , 1993 .

[26]  J. Kunz,et al.  Target of rapamycin in yeast, TOR2, is an essential phosphatidylinositol kinase homolog required for G1 progression , 1993, Cell.

[27]  J J Burbaum,et al.  Improved calcineurin inhibition by yeast FKBP12-drug complexes. Crystallographic and functional analysis. , 1993, The Journal of biological chemistry.

[28]  R F Standaert,et al.  Atomic structures of the human immunophilin FKBP-12 complexes with FK506 and rapamycin. , 1993, Journal of molecular biology.

[29]  S. Schreiber,et al.  A composite FKBP12-FK506 surface that contacts calcineurin , 1993 .

[30]  S. Schreiber,et al.  Activation of an inactive immunophilin by mutagenesis , 1993 .

[31]  N. Sigal,et al.  Characterization of high molecular weight FK-506 binding activities reveals a novel FK-506-binding protein as well as a protein complex. , 1992, The Journal of biological chemistry.

[32]  M. Murcko,et al.  Charged surface residues of FKBP12 participate in formation of the FKBP12-FK506-calcineurin complex. , 1992, The Journal of biological chemistry.

[33]  J. Avruch,et al.  Rapamycin-induced inhibition of the 70-kilodalton S6 protein kinase. , 1992, Science.

[34]  G. Crabtree,et al.  Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases , 1992, Cell.

[35]  S. Schreiber,et al.  The mechanism of action of cyclosporin A and FK506. , 1992, Immunology today.

[36]  G. Crabtree,et al.  Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A , 1991, Nature.

[37]  Stuart L. Schreiber,et al.  Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes , 1991, Cell.

[38]  J. Heitman,et al.  Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast , 1991, Science.

[39]  Ellson Y. Chen,et al.  Overview of manual and automated DNA sequencing by the dideoxy chain termination method , 1991 .

[40]  R F Standaert,et al.  Atomic structure of FKBP-FK506, an immunophilin-immunosuppressant complex , 1991, Science.

[41]  J. Heitman,et al.  FK 506-binding protein proline rotamase is a target for the immunosuppressive agent FK 506 in Saccharomyces cerevisiae. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[42]  N. Sigal,et al.  Is cyclophilin involved in the immunosuppressive and nephrotoxic mechanism of action of cyclosporin A? , 1991, The Journal of experimental medicine.

[43]  L A Herzenberg,et al.  Two distinct signal transmission pathways in T lymphocytes are inhibited by complexes formed between an immunophilin and either FK506 or rapamycin. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[44]  S. Burakoff,et al.  Probing immunosuppressant action with a nonnatural immunophilin ligand , 1990, Science.

[45]  N. Sigal,et al.  The immunosuppressive macrolides FK-506 and rapamycin act as reciprocal antagonists in murine T cells. , 1990, Journal of immunology.

[46]  N. Sigal,et al.  Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin. , 1990, Journal of immunology.

[47]  S. Schreiber,et al.  A receptor for the immuno-suppressant FK506 is a cis–trans peptidyl-prolyl isomerase , 1989, Nature.

[48]  Nolan H. Sigal,et al.  A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin , 1989, Nature.

[49]  R. Sikorski,et al.  A system of shuttle vectors and yeast host strains designed for efficient manipulation of DNA in Saccharomyces cerevisiae. , 1989, Genetics.

[50]  S. Ho,et al.  Site-directed mutagenesis by overlap extension using the polymerase chain reaction. , 1989, Gene.

[51]  T. Kiefhaber,et al.  Cyclophilin and peptidyl-prolyl cis-trans isomerase are probably identical proteins , 1989, Nature.

[52]  T. Hayano,et al.  Peptidyl-prolyl cis-trans isomerase is the cyclosporin A-binding protein cyclophilin , 1989, Nature.

[53]  F. Winston,et al.  A ten-minute DNA preparation from yeast efficiently releases autonomous plasmids for transformation of Escherichia coli. , 1987, Gene.